ERRATUM

In the article by Basser et al entitled ''Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer,'' which appeared in the May 1, 1996 issue (Vol 89, No 9, pp 3118-3128), corrections should be noted. In Table 5 the numbers were misaligned and figure legends 1 and 2 contained errors. The corrected table and figure legends are printed below

Table 5. Nonhematologic Adverse Events in 41 Patients Who Received Study Drug

	Placebo + Filgrastim (n = 10)	PEG-rHuMGDF* + Filgrastim (n = 31)
Local		
Injection site reaction	0 (0)†	2 (6)
Systemic		
Lethargy/drowsiness	1 (10)	17 (55)
Hot flushes/fever*	6 (60) [1]‡	8 (26)
Bone pain	3 (30)	8 (26)
Neurologic		
Headache	6 (60)	13 (42)
Dizziness	3 (30)	12 (38)
Respiratory		
Cough	1 (10)	8 (26)
Dypsnea	3 (30)	12 (38) [3]
Gastrointestinal		
Nausea and/or vomiting	9 (90) [1]	22 (71) [4]
Diarrhea	3 (30)	15 (48) [2]
Mucositis	5 (50)	8 (26)
Metabolic		
Hypokalemia	2 (20)	5 (16)
Thromboembolic		
Thrombophlebitis	0 (0)	1 (3)
Pulmonary embolism	0 (0)	1 (3) [1]§

There was no difference in the frequency of any toxicity between patients given placebo and those administered PEG-rHuMGDF (Fisher's Exact test).

*Not related to neutropenia.

†No. of patients (percentage).

‡Numbers in brackets represent number of events that were grade 3.

§This event was grade 4.

Fig 1. Median platelet counts after chemotherapy for patients given PEF-rHuMGDF 0.03 (▲, n = 3), 0.1 μg/kg (■, n = 3), 0.3 μg/kg (▼, n = 3), 1.0 μg/kg (♦, n = 11), 3.0 μg/kg (●, n = 7), or 5.0 μg/kg (□, n = 4), and placebo (△, n = 10). The horizontal bar indicates a platelet count of 100 × 10^9/L.

Fig 2. (A) shows platelet recovery for all patients given PEG-rHuMGDF (■, n = 25) and those given placebo (△, n = 10). (B) shows the Kaplan-Meier plot of the probability of recovery to baseline platelet counts in these groups. The median time to baseline counts was 18 days for PEG-rHuMGDF and 22 days for placebo (P = .014, log rank test).